Drug Profile

AL 78898A

Alternative Names: AL-78898A; Compstatin analogue; POT-4

Latest Information Update: 22 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Pennsylvania
Developer Alcon
Class Cyclic peptides; Eye disorder therapies
Mechanism of Action Complement C3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Age-related macular degeneration; Dry age-related macular degeneration

Most Recent Events

14 May 2026 Apellis Pharmaceuticals has been acquired by Biogen
09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
23 Nov 2014 Apellis Pharmaceuticals enters into an agreement to acquire Potentia Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com